(Q81354813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

main subject

phase III clinical trial

1 reference

multicenter clinical trial

inferred from title

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Christopher Griffiths

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Kristian Reich

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Frank O Nestle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jean-Paul Ortonne

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Robert Evans

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Cynthia Guzzo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Shu Li

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Lisa T Dooley

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

EXPRESS study investigators

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

9494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1367-1374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

1 reference

7 January 2021

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Biological therapies in the systemic management of psoriasis: International Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Infectious complications of tumor necrosis factor-alpha antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Safety of tumour necrosis factor-alpha antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967566-6

7 January 2021

10.1016/S0140-6736(05)67566-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226614%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference